All In MedTech

Device Trial Radar · NCT06970171

Acceptance of Mandibular Advancement Devices

Acceptance and Side Effects of Two Different Mandibular Advancement Devices (MADs) in the Treatment of Obstructive Sleep Apnea Syndrome (OSAS)

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

28

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

May 5, 2027

Study completion May 1, 2028

Sponsor

Lead sponsor
University Medicine GreifswaldAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 14, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Obstructive sleep apnea syndrome (OSAS) is a prevalent condition with significant comorbidities. Mandibular advancement devices (MADs) are an established alternative for patients intolerant to continuous positive airway pressure (CPAP) therapy. However, potential side effects, particularly within the craniomandibular system, warrant further investigation. Objective: This randomized controlled Phase IV trial aims to compare two different MAD designs (UPS-1 by Scheu Dental and UPS-2 by Panthera X3) in terms of patient acceptance, wearing comfort, adherence, and side effects, especially occlusal changes and temporomandibular discomfort, in OSAS patients over a 12-month period. Methods: Twenty-eight patients will be stratified by sex and randomized 1:1 into two treatment groups. Assessments include acceptance of the MAD, clinical and digital occlusal analysis (GEDAS), functional examination (DC/TMD), sleep parameters (AHI, ESS, DI), and patient-reported outcomes. Follow-ups were scheduled at 4 weeks, 6 months, and 12 months post-insertion. Data were collected using standardized CRFs and validated questionnaires. Statistical analysis was based on ordinal regression and intention-to-treat and per-protocol populations. Results \& Conclusion: This study will provide evidence on the comparative efficacy and tolerability of two distinct MAD systems, contributing to improved treatment selection in personalized OSAS management.

Conditions

  • Obstructive Sleep Apnea Syndrome (OSAS)

Interventions

  • MAD of the Scheu Dental type with lateral guidance wings (MAD-1)Device

    The vertical dimension is raised to achieve an incisal edge distance (IED) of 5 mm using a George Gauge, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.

  • MAD of the Panthera X3 type with lateral guidance wings (MAD-2)Device

    The vertical dimension is raised to achieve a minimum 2 mm interocclusal cusp distance and the lowest possible IED, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acceptance of the MADTime frame: 4 weeks, 6 months, 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medicine Greifswald, Department of Restorative Dentistry, Periodontology and Endodontology

    Greifswald, Mecklenburg-Vorpommern, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.